Want to see IDYA full AI Analyst Report?
IDYA Stock Chart & Stats
$35.40
-$0.83(-2.29%)
At close: 4:00 PM EDT
$35.40
-$0.83(-2.29%)
Day’s Range― - ―
52-Week Range$23.23 - $42.68
Previous CloseN/A
Volume901.71K
Average Volume (3M)1.20M
Market Cap
$4.01B
Enterprise Value$2.63K
Total Cash (Recent Filing)$828.96M
Total Debt (Recent Filing)$29.31M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 10, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding96,489,490
10 Day Avg. Volume777,077
30 Day Avg. Volume1,197,127
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.55Price Target Upside45.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.57
Revenue Forecast (FY)$38.33M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetMinimal leverage and substantial assets provide financial flexibility to fund clinical development, absorb biotech volatility, and limit near-term dependence on debt markets while the pipeline advances toward potential commercialization.
Positive Late-stage Clinical ValidationMeeting the registrational trial endpoint, with consistent subgroup benefit and FDA Real-Time Oncology Review, strengthens the probability of a future commercial asset and could establish a differentiated position in underserved uveal melanoma.
Strategic Precision-oncology CollaborationRoche’s participation expands IDEAYA’s clinical development capabilities and validates its biomarker-driven approach. Combination testing may broaden the addressable opportunity in cancers lacking approved targeted therapies.
Bears Say
Deep Ongoing LossesIDEAYA remains far from break-even despite revenue acceleration and improving losses. Sustained negative margins mean future pipeline progress must generate substantial partnering or product economics before the business can become self-sustaining.
Persistent Cash BurnClinical trials and research continue to consume significant cash, and operations are not self-funding. Even with improved burn versus 2024, continued spending creates an ongoing need for external capital or successful milestones.
Equity Financing DilutionThe raise materially strengthens liquidity but expands the share base and creates potential dilution for existing holders. Repeated equity financing may remain necessary while IDEAYA lacks marketed products and recurring operating revenue.
IDEAYA Biosciences News
IDYA FAQ
What was Ideaya Biosciences’s price range in the past 12 months?
Ideaya Biosciences lowest stock price was $23.23 and its highest was $42.68 in the past 12 months.
What is Ideaya Biosciences’s market cap?
Ideaya Biosciences’s market cap is $4.01B.
When is Ideaya Biosciences’s upcoming earnings report date?
Ideaya Biosciences’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were Ideaya Biosciences’s earnings last quarter?
Ideaya Biosciences released its earnings results on Aug 04, 2026. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.163.
Is Ideaya Biosciences overvalued?
According to Wall Street analysts Ideaya Biosciences’s price is currently Undervalued.
Does Ideaya Biosciences pay dividends?
Ideaya Biosciences does not currently pay dividends.
What is Ideaya Biosciences’s EPS estimate?
Ideaya Biosciences’s EPS estimate is -1.18.
How many shares outstanding does Ideaya Biosciences have?
Ideaya Biosciences has 96,489,490 shares outstanding.
What happened to Ideaya Biosciences’s price movement after its last earnings report?
Ideaya Biosciences reported an EPS of -$1.22 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went up 2.006%.
Which hedge fund is a major shareholder of Ideaya Biosciences?
Currently, no hedge funds are holding shares in IDYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEAYA Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.55 (45.61% Upside)
$51.55 (45.61% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.78%
Trailing 12-Months
Company Description
Ideaya Biosciences
IDEAYA Biosciences, Inc. (IDYA) is a clinical-stage precision oncology company in the biotechnology sector focused on discovering and developing targeted therapeutics and molecular diagnostics for genetically defined cancers. The company’s pipeline is built around synthetic lethality and other precision-medicine approaches, with drug candidates designed to treat patient populations selected by specific tumor biomarkers.
IDYA Stock 12 Month Forecast
Average Price Target
$51.55
▲(45.61% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Celcuity
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
0.81% Insiders
27.51% Mutual Funds
33.22% Other Institutional Investors
23.02% Public Companies and
Individual Investors